Brief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
19/08/2026 13:29
BRIEF-Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update Aug 19 (Reuters) - Chemomab Therapeutics Ltd CMMB.O:
CHEMOMAB THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CHEMOMAB THERAPEUTICS LTD - NEBOKITUG RA PHASE 2 CLINICAL TRIAL EXPECTED TO BEGIN IN H1 2027 AND READ OUT IN H1 2028
CHEMOMAB THERAPEUTICS LTD - CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS WERE $6.7 MILLION AS OF JUNE 30, 2026
Source text: ID:nGNX9H2RNt
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update